CAPR - Dosing underway in Capricor Therapeutics' mid-stage CAP-1002 study in COVID-19

The first two patients have been dosed in Capricor Therapeutics' (CAPR) Phase 2 study evaluating intravenous infusion of CAP-1002 – its lead clinical asset - using allogeneic cardiosphere-derived cells ((CDC)) technology as a treatment option for patients with COVID-19.The study will enroll up to 60 patients who have been diagnosed with SARS-CoV-2 and require supplemental oxygen. The primary objectives of the Phase 2 INSPIRE trial are to determine the safety and effectiveness of CAP-1002 for improving clinical outcomes in COVID-19 patients.Eligible subjects will be randomized to either the CAP-1002 or placebo group (1:1 ratio) and undergo baseline safety and efficacy assessments approx. one to three days prior to the administration of investigational product.Shares up 4% premarket.

For further details see:

Dosing underway in Capricor Therapeutics' mid-stage CAP-1002 study in COVID-19